Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Celgene to Expand Strategic Collaboration Scope with FORMA Therapeutics

By Celgene | September 1, 2017

In 2014, FORMA Therapeutics and Celgene Corporation announced an innovative R&D partnership to pursue ground-breaking medicines in oncology and other therapeutic areas. Today, FORMA announced that Celgene has exercised its option, pursuant to the 2014 collaboration arrangement, to extend its strategic collaboration with FORMA by entering into a second collaboration agreement to evaluate additional therapeutic candidates across important emerging target families in the areas of protein homeostasis, inflammation & immunology, and neurodegeneration.

Upon execution of this agreement, FORMA received an upfront cash payment of $195 million and Celgene was granted an option to license ex-U.S. rights to select current and future drug candidates through October 1, 2019. Celgene will assume responsibility for all global development activities and costs for in-licensed drug candidates after completion of Phase 1 clinical trials. Under the agreement, FORMA will be eligible to receive milestone payments for licensed drug candidates if certain development, regulatory and sales milestones are achieved. FORMA retains U.S. rights to all such licensed assets, including responsibility for manufacturing and commercialization in their territory. For products not licensed to Celgene, FORMA will maintain worldwide rights.

In addition, also pursuant to the 2014 collaboration arrangement, Celgene retains the option to enter into one additional collaboration agreement, during which Celgene will have the exclusive option to acquire FORMA, including the U.S. rights to all Celgene-licensed programs, and worldwide rights to other unencumbered, wholly-owned programs within FORMA at that time.

“Our continued collaboration with FORMA is based upon the quality of their drug candidates, their adaptability to enter new emerging areas of biology, and their leadership in fostering a collaborative culture at the forefront of innovation,” said Rupert Vessey, FRCP, DPhil, President of Research and Early Development, Celgene Corporation.

“FORMA has made significant advances by declaring multiple drug candidates with the potential for profound differentiation across a broad range of therapeutic areas, and to date has advanced several Celgene-partnered or wholly-owned by FORMA into the clinic,” said Steven Tregay, Ph.D., CEO and Founder, FORMA Therapeutics. “The continued expansion of our partnership provides FORMA with sustainability and autonomy to deliver on our research strategy, which aligns well with Celgene’s global strategic directives.”

John Hohneker, M.D., President, Research and Development, FORMA Therapeutics, added, “We are thrilled that Celgene values the innovative science that we are pursuing at FORMA. The continuation of our productive collaboration is a tribute to our team of talented scientists and clinicians who have and continue to bring forth potentially important new medicines for people with cancer and other serious diseases.”


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50